Drug-resistant bacteria and fungi are evolving at a rapid pace. Within three decades, these “superbugs,” could kill up to 10 million people each year. Working to Fight AMR seeks to combat this public health crisis by stimulating the production of new antimicrobial medicines. Scientists have developed only one truly novel antibiotic since 1984, and just 1% of medicines in development globally address bacterial infections.
Without effective antibiotics, infections like UTIs will become very difficult to treat, and surgeries and cancer treatment will become even riskier. We have time to change this bleak future; we have time to turn American innovation into life-saving cures; you have time to send a message to Washington today.
The economics of this issue are upside down, but there are smart policies in Congress that could catalyze the creation of new antimicrobials.
We need your help.
Action in Congress could accelerate the creation of new antimicrobials. To ensure that Washington, D.C. understands the urgency of this crisis, lawmakers need to hear from you. Use this form to easily send a video or message to your elected representatives and tell them to help stop the spread of superbugs by passing impactful legislation that encourages private sector investment, starting with the DISARM Act.
Without effective antimicrobials, we will return to the medical dark ages.
Many companies have stopped investing in antibiotic research.
Diseases know no borders, and we are currently unable to stop the invasion of harmful bacteria.
Rapid genomic tests are poised to change the way doctors diagnose and treat infections, but their cost may limit widespread…Read More
There's a silent, invisible killer among us. Walls, borders, even oceans can't stop it. It's a drug-resistant microbe. Trillions of…Read More
Health experts recommend doctors examine patients, seek testing to verify antibiotics are necessary Patients widely received antibiotics with no record…Read More
W.H.O. Warns That Pipeline for New Antibiotics Is Running Dry With the pipeline for new antibiotics slowing to a trickle…Read More